Hikma Eyes Another Hybrid Injectable With Arecor

Second Agreement Using 505(b)(2) Pathway

London-listed Hikma has signed a second partnership agreement with Arecor, proposing to co-develop a 505(b)(2) hybrid injectable product for the US market.

Handshake
Hikma and Arecor have shaken hands on another hybrid injectable co-development agreement • Source: Shutterstock

Hikma has strengthened its partnership with UK-based Arecor, signing a second agreement to co-develop an undisclosed, ready-to-use injectable to be filed through the US Food and Drug Administration’s 505(b)(2) hybrid regulatory pathway.

Under the terms of the royalty-based agreement, Arecor will receive an upfront payment and further payments on the achievement of...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business